News

Today, the Biden-Harris administration announced the new, lower prices for 10 of the highest-cost, most popular drugs taken by people on Medicare. These new prices are the highest prices drug companies can charge for these lifesaving medications – all made possible through the historic Inflation Reduction Act, passed by Democrats in Congress and the Biden-Harris administration in 2022, which gave Medicare the power to negotiate lower drug prices with manufacturers for the first time in history.

This announcement follows a long line of actions the Biden-Harris administration has taken to reduce prescription drug and health care costs for the American people. The Inflation Reduction Act also lowered drug prices for millions of seniors by capping insulin costs at $35 per month, limiting outrageous price hikes, and making recommended vaccines like shingles free for people on Medicare. And starting in 2025, total out-of-pocket drug costs will be capped at $2,000 per year for seniors. In 2023, 10 million seniors received a free vaccine, and HHS estimates that 19 million seniors will save $400 or more per year thanks to the out-of-pocket cap.

At the same time, Donald Trump and Republicans in Congress are fighting to roll back this progress and repeal the Inflation Reduction Act’s historic measures to lower drug prices for seniors. Just weeks after Trump’s inauguration in 2017, he dropped his promise to negotiate drug prices after meeting with big drug company lobbyists. Now, he wants to ban Medicare from negotiating down prices for millions of Americans. Repealing these policies would cost seniors billions of dollars — only putting money back in the pockets of big drug companies.

Administration 

President Joe Biden: “Today, for the first time in history, my Administration is announcing that Medicare has reached agreements on new, lower prices with the manufacturers of all 10 drugs selected for the first round of drug price negotiation. […] This historic milestone is only possible because of the Inflation Reduction Act, which passed with the leadership of Democrats in Congress, and with Vice President Harris casting the tie-breaking vote in the Senate – without a single Republican voting for it. We showed that major progress can be made for the American people when we work together to take on special interests, even as Big Pharma continues to go to court to try to block lower prices for consumers. But the Vice President and I are not backing down. We will continue the fight to make sure all Americans can pay less for prescription drugs and to give more breathing room for American families.” [President Joe Biden, Statement, 8/15/24]

Vice President Kamala Harris: “Thanks to our historic work to allow Medicare to negotiate lower drug prices, millions of Americans who rely on these drugs will save on their out-of-pocket costs. While people enrolled in Medicare are expected to save $1.5 billion in 2026 alone, American taxpayers will also save an estimated $6 billion. Today’s announcement will be life changing for so many of our loved ones across the nation, and we are not stopping here. Additional prescription drugs will be selected each year as part of our Medicare drug price negotiation program. This includes up to 15 additional drugs covered under Medicare Part D for negotiation in 2025, up to an additional 15 Part B and Part D drugs in 2026, and up to 20 drugs every year after that.” [Vice President Kamala Harris, Statement, 8/15/24]

Xavier Becerra, Secretary of Health and Human Services: “Americans pay too much for their prescription drugs. That makes today’s announcement historic. For the first time ever, Medicare negotiated directly with drug companies and the American people are better off for it. Congressional budget estimators (Congressional Budget Office) predicted about $100 billion savings over 10 years from drug negotiations, and a $3.7 billion savings in the first year alone. Today we’re announcing that in our first year of negotiations we are saving Medicare an estimated $6 billion and Americans who pay out of pocket will be saving another $1.5 billion moving forward. Empowering Medicare to negotiate prices not only strengthens the program for generations to come, but also puts a check on skyrocketing drug prices.” [CMS Press Release, 8/15/24]

Chiquita Brooks-LaSure, Administrator for the Centers for Medicare and Medicaid Services: “CMS is proud to have negotiated drug prices for people with Medicare for the first time. These negotiations will not only lower the prices of critically important medications for cancer, diabetes, heart failure, and more, but will also save billions of dollars. Medicare drug price negotiation and the lower prices announced today demonstrate the commitment of CMS and the Biden-Harris Administration to lower health care and prescription drug costs for Americans. We made a promise to the American people, and today, we are thrilled to share that we have fulfilled that promise.” [CMS Press Release, 8/15/24]

Meena Seshamani, CMS Deputy Administrator and Director of the Center for Medicare: “CMS negotiated in good faith on behalf of the millions of people who rely on these 10 drugs for their health and well-being. The new negotiated prices will bring much needed financial relief, affordability, and access. Throughout the process, we remained true to our commitment to be thoughtful and transparent, meeting publicly with patients, providers, health plans, pharmacies, drug companies and others to help inform the process. We will continue to do so for future cycles. Our team is actively working on the next cycle of negotiations where we will combine what we have learned from this first cycle and apply it in negotiating prices for the next round of up to 15 selected drugs.” [CMS Press Release, 8/15/24]

Neera Tanden, White House Domestic Policy Advisor: “Because Medicare is now able to negotiate lower prescription drug prices for seniors, American taxpayers are expected to save $6 billion on these 10 drugs alone when the negotiated prices go into effect.” [The Hill, 8/15/24]

Congress

Speaker Emerita Nancy Pelosi (D-CA-11): “This is an historic and transformative day. The Inflation Reduction Act was a monumental victory in Democrats’ long fight to make prescription drugs more affordable: empowering Medicare to negotiate lower prices. Under the leadership of the Biden-Harris Administration, today’s announcement delivers billions of dollars in savings for millions of American seniors. Democrats will never stop fighting to build on this progress and keep lowering costs for America’s working families.” [X, 8/15/24]

President Pro Tempore Patty Murray (D-WA): “This is the biggest step we have taken in over a decade to bring down drug prices—all because of Democrats’ Inflation Reduction Act. Not only did every single Republican vote against it, but—as Project 2025 makes clear—Republicans are still scheming to repeal the entire IRA under a Trump admin regardless of how that might hurt families.” [X, 8/15/24]

Majority Leader Chuck Schumer (D-NY): “Today’s announcement is a huge, long-sought-after breakthrough for American families. For decades, the American people wanted fair negotiations with Big Pharma, and because of the Inflation Reduction Act, they got it. Now the American people are seeing the results.” [X, 8/15/24]

Majority Whip Dick Durbin (D-IL): “The Biden-Harris Administration announced that 10 of the most costly and prescribed drugs are having their prices cut—some up to 79%—saving Americans billions on prescription drug prices. @POTUS & Senate Dems will continue to deliver through the Inflation Reduction Act.” [X, 8/15/24]

Chair of Policy & Communications Debbie Stabenow (D-MI): “BIG NEWS: @POTUS & @VP have negotiated lower costs for 10 prescription drugs! These are drugs seniors use every day for diabetes, blood clots, and cancers. About nine million people in the U.S. use one of these ten drugs & will see their costs lowered next year!” [X, 8/15/24]

Senate Finance Committee Chair Ron Wyden (D-OR): “Today, Medicare has used the bargaining power of tens of millions of American seniors to fight Big Pharma for lower drug prices,” Wyden said. “While Trump and his Republican allies in Congress want to leave Big Pharma in charge so seniors pay higher prices, Democrats have delivered lower costs, more consumer protections, and accountability of drug companies that raise prices with impunity. These new, lower prices for prescription drugs in Medicare means seniors save money at the pharmacy counter and marks the first step in a seismic shift in the relationship between Big Pharma, taxpayers, and seniors who need affordable prescription drugs.” [Senate Committee on Finance Press Release, 8/15/24]

Senate HELP Committee Chair Bernie Sanders (I-VT): “Let me congratulate the Biden-Harris Administration for taking on the greed of the pharmaceutical industry & slashing the list prices of some of the most expensive prescription drugs under Medicare by up to 79%. This action will bring significant financial relief to seniors.” [X, 8/15/24]

Senate Rules Committee Chair Amy Klobuchar (D-MN): “Exorbitant prices should never stand between Americans and the life-sustaining medications they need. That is why I worked to end the sweetheart deal that allowed Big Pharma to artificially raise prices at the expense of our seniors. This announcement will save patients and taxpayers billions of dollars and these savings will grow as Medicare negotiates the prices of even more drugs. Seniors won’t be the only ones to benefit. These prices will give employers and commercial health plans important information they need to secure savings for Americans with private insurance too. This is a major turning point in our fight to bring down costs.” [Press Release, 8/15/24]

Senator Bob Casey (D-PA): “For far too long, prescription drug costs have hung like a bag of rocks tied around the necks of millions of Americans, weighing them down every single day,” said Chairman Casey. “I fought to give Medicare the power to negotiate prices with drug companies to help ease the burden that so many older Americans are carrying. Today’s announcement is a huge relief for the people who rely on these often life-saving medications, and shows just how significant the savings will be as Medicare plans to engage in price negotiations on more and more drugs in the coming years.” [Press Release, 8/15/24]

Senator Jon Tester (D-MT): “Montanans shouldn’t have to struggle to fill their lifesaving prescription medications because Big Pharma is jacking up prices, and today’s announcement is a big win for Montanans across our state. That’s why I took the large pharmaceutical companies head-on to pass a commonsense law that will now officially lower the cost of 10 of the most common prescription drugs that Montanans rely on that treat heart disease, cancer, diabetes, blood clots, and more. I’ll continue working to lower costs and put more money back in the pockets of hardworking families.” [Press Release, 8/15/24]

Minority Whip Katherine Clark (D-MA-05): “A major win for seniors! This is what happens when our leaders prioritize people over profits.” [X, 8/15/24]

House Energy and Commerce Committee Ranking Member Frank Pallone (D-NJ-06): “This is a historic day. Democrats fought for over 20 years to empower Medicare to negotiate lower prescription drug prices for seniors. Today we have finally achieved that goal. As a result of these negotiations, Americans are expected to save $1.5 billion in the first year alone. And this is just the beginning. Now that Medicare has the authority to negotiate, it will continue to negotiate lower prices on more drugs each year going forward. It is a gamechanger that will save American seniors’ hard-earned money for years to come. While Republicans want to repeal this progress and allow Big Pharma to raise prices, Democrats are just getting started. We’re defending the progress we’ve made while continuing to fight to further lower prescription drug prices.” [Congressman Frank Pallone Jr. Press Release, 8/15/24]

House Ways and Means Committee Ranking Member Richard Neal (D-MA-01): “Tomorrow’s second anniversary of the Inflation Reduction Act is now that much more momentous with today’s announcement of the first slate of lower prescription drug prices negotiated by the Biden-Harris Administration. We are fighting back against Big Pharma’s ‘profits over people’ practice and putting an end to the heartbreaking decisions between medical care and life’s other responsibilities. Not only will seniors save $1.5 billion on out-of-pocket costs in the first year alone, but Medicare will also save $6 billion. It’s commonsense: strengthening our health care system while saving taxpayers money.” [House Ways and Means Committee Democrats, Press Release, 8/15/24]

House Education & Labor Committee Ranking Member Bobby Scott (D-VA-03) “Democrats beat Big Pharma when we enacted the Inflation Reduction Act. This law finally empowered Medicare to negotiate lower prescription drug prices. Today’s announcement from the Biden-Harris Administration will deliver massive savings for millions of seniors.” [X, 8/15/24]

Chair of the Congressional Asian Pacific American Caucus Representative Judy Chu (D-CA-28): “Exciting News! Thanks to the Inflation Reduction Act, the @WhiteHouse negotiated lower prices for 🔟 Medicare drugs. 💊 American taxpayers are expected to save $6 billion on Rx drugs 💲Medicare enrollees are expected to save $1.5 billion in out-of-pocket Rx costs in 2026 alone” [X, 8/15/24]

Advocates

AARP’s Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond: “Today’s announcement marks a significant step forward in our long-standing efforts to lower prescription drug prices. AARP members from across the political spectrum overwhelmingly called lowering prescription drug costs a top concern – and this first round of Medicare-negotiated prices will bring financial relief to millions of older Americans. As the voice for the 100 million Americans ages 50-plus, we will continue working to ensure this law is fully implemented and benefits older Americans for decades to come.” [AARP, 8/15/24]

Accountable.US’ Executive Director Tony Carrk: “This is a transformative victory for millions of seniors and other patients who rely on Medicare for affordable access to life-saving medications. Big Pharma CEOs and their army of lobbyists spared no expense to defend a system rigged in their favor, prioritizing profits and price gouging over people’s health. The Biden-Harris administration has made the well-being of millions of Americans the priority, taking a decisive step towards lowering c2osts for millions.” [Press Release, 8/15/24]

Building Back Together’s Deputy Director of Strategic Initiatives Eileen Garcia: “Today marks a key moment in America’s history. Thanks to the Inflation Reduction Act — passed as a result of Vice President Harris’ historic tie-breaking vote in the Senate and signed by President Biden — Medicare has resolved its first-ever negotiations with Big Pharma, lowering the cost of ten of the most commonly used prescriptions in the country. … From day one of this administration, President Biden and Vice President Harris have stood firm in the face of big corporations to bring down prices and ease the financial burdens plaguing working people. The fact is, medications don’t work if people can’t afford to take them; now, more people will be able to access the critical care they need to live healthier lives, and that is a fact worth celebrating.” [Press Release, 8/15/24]

Center for American Progress’ Vice President of Health Policy Andrea Ducas: “Today’s announcement marks a historic moment for the Medicare program. Thanks to the Biden-Harris administration, seniors will benefit from price cuts for lifesaving drugs, which will put cash back in their pockets. For decades, Big Pharma has raked in record profits, with America’s seniors paying the price. Essential drugs to treat cancer and blood clots and to manage chronic conditions should not be priced out of reach to pad pharmaceutical companies’ bottom lines. In addition to the IRA’s $2,000 Medicare Part D out-of-pocket cost cap, inflation rebates, and $35 monthly cost cap on insulin, today’s negotiated prices are another example of how the IRA and the Biden-Harris administration are delivering much-needed relief to millions of Medicare beneficiaries.” [Press Release, 8/15/24]

Health Care For America Now’s Executive Director Margarida Jorge: “As the Inflation Reduction Act turns two this week, today’s news about lowered prices through Medicare negotiations gives patients, providers and taxpayers alike something big to celebrate. … And this is just the beginning. More drugs will be selected each year as part of Medicare’s drug price negotiation program which will save patients and taxpayers even more money over the coming decade and make medicines more accessible for seniors and people with disabilities.” [Press Release, 8/15/24]

Patients For Affordable Drugs’ Executive Director Merith Basey: “For the first time in its 59-year history, Medicare has ushered in a new era of affordability for patients across the country by successfully negotiating lower prices on 10 of the most expensive and widely-used drugs. Medicare Negotiation alters the trajectory of drug pricing in the U.S. and begins to break the monopoly power of big drug corporations to dictate prices of brand-name drugs to people in this country. It marks a critical shift in the system to make it work for the people it is supposed to serve – patients – rather than those who profit from it. The lower negotiated prices symbolize new hope for patients on these drugs who have been forced to make impossible choices between their health, well-being, and financial stability.” [Press Release, 8/15/24]

Public Citizen’s Access to Medicines Director Peter Maybarduk: “This is a major achievement. At last and over Big Pharma’s pernicious, hand-wringing opposition, Medicare has negotiated drug prices, promising long-overdue savings for American taxpayers.” [Press Release, 8/15/24]

Small Business for America’s Future Senior Advisor Rhett Buttle: “The Inflation Reduction Act gave Medicare the authority to negotiate lower drug prices, which marked another important step toward increased affordability that will have far-reaching impacts on the entire healthcare system. Today’s announcement of the negotiated prices for 10 key medications, set to take effect in 2026, is a clear demonstration of this policy in action. … By addressing high healthcare costs, we’re strengthening small businesses and the overall health of our national economy. I encourage lawmakers to prioritize more policies like the Inflation Reduction Act to sustain small business growth.” [Press Release, 8/15/24]

While Republicans Vow to Ban Medicare from Negotiating, Democrats Deliver Lower Drug Prices 

Today, the Biden-Harris administration announced the new, lower prices for 10 of the highest-cost, most popular drugs taken by people on Medicare. These new prices are the highest prices drug companies can charge for these lifesaving medications – all made possible through the historic Inflation Reduction Act, passed by Democrats in Congress and the Biden-Harris administration in 2022, which gave Medicare the power to negotiate lower drug prices with manufacturers for the first time in history.

This announcement follows a long line of actions the Biden-Harris administration has taken to reduce prescription drug and health care costs for the American people. The Inflation Reduction Act also lowered drug prices for millions of seniors by capping insulin costs at $35 per month, limiting outrageous price hikes, and making recommended vaccines like shingles free for people on Medicare. And starting in 2025, total out-of-pocket drug costs will be capped at $2,000 per year for seniors. In 2023, 10 million seniors received a free vaccine, and HHS estimates that 19 million seniors will save $400 or more per year thanks to the out-of-pocket cap.

At the same time, Donald Trump and Republicans in Congress are fighting to roll back this progress and repeal the Inflation Reduction Act’s historic measures to lower drug prices for seniors. Just weeks after Trump’s inauguration in 2017, he dropped his promise to negotiate drug prices after meeting with big drug company lobbyists. Now, he wants to ban Medicare from negotiating down prices for millions of Americans. Repealing these policies would cost seniors billions of dollars — only putting money back in the pockets of big drug companies.

BY THE NUMBERS

• In the first year alone, these newly lowered prices will save seniors $1.5 billion in out-of-pocket costs and will save taxpayers $6 billion.
• The Medicare Drug Price Negotiation will slash the list prices of the first ten drugs by 38–79 percent.
• The first ten drugs selected are taken by nearly 9 million people on Medicare, who spent $3.9 billion in out-of-pocket costs in 2023 alone.
• Drug companies routinely charge Americans up to eight times more than patients in other countries for the same prescriptions.

HEADLINES

The Washington Post: Medicare Negotiations With Drug Companies Saved $6 Billion, Democrats Say.

• “A year-long effort to negotiate with pharmaceutical companies over some of the priciest drugs used by older Americans has resulted in about $6 billion in initial savings, Biden administration officials told reporters, with implications for many patients’ out-of-pocket spending. The new, negotiated prices ranged from 38 to 79 percent lower compared with the drugs’ list prices in 2023. […] For nine of the drugs, the negotiations help cut the price by more than 50 percent, officials said.”
• “Democrats and their allies are heralding the initiative as a crowning achievement after years of battling with the pharmaceutical industry. The initiative is set to be scaled up, with Medicare planning to target 15 additional drugs for negotiations in 2025 and 2026, and 20 drugs a year subsequently.”
• “‘The Biden-Harris administration and Democrats in Congress stood up to the greed of big drug companies and won,’ Leslie Dach, the chair of Protect Our Care, a Democratic-aligned group, said in a statement. ‘Now, prices will come down for millions of seniors.’”

Rolling Stone: Dems Prove What Other Countries Know: Negotiating Drug Prices Works.

• “Congress for decades prohibited Medicare from negotiating drug prices, something that virtually all other countries do. It’s a chief reason why drug prices are two to four times higher in the United States than in other wealthy countries. The negotiated price list released by the administration on Thursday shows what Americans have been missing out on: Medicare will pay less than half of the current list prices on nine of the first 10 drugs that were included in the program.”
• “The basic reality is that Americans have been forced to pay the world’s highest prices for lifesaving products they helped finance. This status quo remains, but under Biden, Democrats finally fulfilled their longtime pledge to allow Medicare to negotiate drug prices. Some conservative Democrats helped water down the provision — limiting the number and types of drugs that would be subject to negotiation, and who will benefit — but the program’s successful inclusion as part of the 2022 Inflation Reduction Act was historic — and it opens the door to further expansions down the line.”

The New York Times: U.S. Announces Prices for First Drugs Picked for Medicare Negotiations.

• “The prices of the drugs, which include widely used blood thinners and arthritis medications, will take effect in 2026. They represent the first time that the federal government has directly negotiated with drugmakers on behalf of Medicare beneficiaries, and will reshape the federal government’s role in a program that covers tens of millions of older and disabled Americans.”
• “The prices the Biden administration announced were made possible by the Inflation Reduction Act, a climate, health and tax bill signed by Mr. Biden in 2022 that granted the health and human services secretary the authority to negotiate on behalf of Medicare. The law delivered more immediate benefits to the program’s beneficiaries, including a $35 monthly cap on out-of-pocket costs for insulin, and a $2,000 annual cap on patient costs for drugs taken at home. The $2,000 limit will go into effect next year.”
• “The selected drugs account for some of the highest Medicare spending, have been on the market for years and do not face competition. Medicare officials are not required to publish explanations of how the federal government arrived at the negotiated prices until March. The number of drugs negotiated by the federal government is set to increase in the coming years. President Biden has called for Medicare to negotiate the prices of 500 drugs over the next decade.”

NPR: Medicare Negotiated Drug Prices For The First Time. Here’s What It Got.

• “The White House unveiled the fruits of months of negotiations between the government and pharmaceutical companies: new, lower Medicare prices for 10 blockbuster drugs. The discounts range from 79% for diabetes drug Januvia to 38% for blood cancer drug Imbruvica. If the negotiated prices were in effect in 2023, Medicare would have saved $6 billion and beneficiaries would have saved $1.5 billion in out-of-pocket costs, such as copays at the pharmacy counter. That’s what officials say they expect to save in the first year the prices are in effect.”
• “It’s expected Medicare drug price negotiations will save the government $98.5 billion over a decade, according to the Congressional Budget Office, which scored the Inflation Reduction Act.”
• “The pharmaceutical industry has pushed back against the negotiations, filing several lawsuits to keep the negotiated prices from going into effect and saying the move will be bad for drug innovation. However, the CBO estimates that the Inflation Reduction Act will prevent 13 new drugs from coming to market over the next 30 years out of the 1,300 of them that are expected to come to market over that time. Over the past few weeks, several drug companies involved in this round of negotiations told their investors they are able to manage the losses from lower Medicare prices.”

STAT: Medicare Announces Drug Prices For Historic First Round Of Negotiations.

• “Medicare officials on Thursday unveiled the results of the program’s first 10 drug price negotiations, despite the industry’s two-decade, multimillion-dollar lobbying campaign and barrage of lawsuits to stop them.”
• “Several drugmakers and their allies have challenged the law as unconstitutional in court, though the pharmaceutical industry’s side has lost every ruling so far. Many of the cases are still in process, either waiting on a ruling or working their way through the appeals process. […] In the meantime, drugmakers have largely painted a rosy picture to investors about being able to manage the effects of the negotiation program to their bottom lines, though they warn of a downstream impact in the future.”

CNBC: Biden Administration Releases Prices Of 10 Drugs In Medicare Negotiations, Says Us Will Save $6 Billion In First Year. 

• “The Biden administration on Thursday released prices for the first 10 prescription drugs that were subject to landmark negotiations between drugmakers and Medicare, a milestone in a controversial process that aims to make costly medications more affordable for older Americans. The government estimates that the new negotiated prices for the medications will lead to around $6 billion in net savings for the Medicare program in 2026 alone when they officially go into effect, or 22% net savings overall. That is based on the estimated savings the prices would have produced if they were in effect in 2023, senior administration officials told reporters on Wednesday. The Biden administration also expects the new prices to save Medicare enrollees $1.5 billion in out-of-pocket costs in 2026 alone.”
• “The negotiations are the centerpiece of the Biden administration’s efforts to rein in the rising cost of medications in the U.S. Some congressional Democrats and consumer advocates have long pushed for the change, as many seniors around the country struggle to afford care. The price talks are expected to save money for people enrolled in Medicare, who take an average of four to five prescription drugs a month. Almost 10% of Medicare enrollees ages 65 and older, and 20% of those under 65, report challenges in affording drugs, a senior administration official told reporters last year.”

The Hill: Medicare Talks To Yield $6B In Savings.

• “The first round of Medicare drug price negotiations will save an estimated $6 billion, according to the Biden administration. Six months of negotiations for the first 10 drugs chosen by the program ended on Aug. 1 and agreements were reached for all of the medications according to White House officials.”
• “From that amount, Medicare enrollees are projected to save $1.5 billion when the prices go into effect in 2026. The drugs were chosen for being among the highest total Part D gross covered prescription drug costs, an estimated $50.5 billion. The medications that were chosen treat conditions like heart failure, diabetes, rheumatoid arthritis and blood cancers.”

CNN: Medicare And Its Enrollees To Save Billions From Historic Drug Price Negotiations, Biden Administration Says. 

• “The $6 billion in savings for Medicare represents a 22% reduction in total net spending on the medications, which factors in the rebates and discounts. Officials cannot provide details about the net cost cuts for each medicine since it is competitive information. The initial round of negotiations with drugmakers – who have been trying, unsuccessfully so far, to quash the program in federal court – focused on the most widely used and expensive drugs taken by Medicare enrollees. The medications are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica and Stelara, as well as Fiasp and certain other insulins made by Novo Nordisk, including NovoLog.”
• “The $6 billion in savings estimate is based on Medicare’s 2023 cost for these drugs, Chiquita Brooks-LaSure, administrator of the Centers for Medicare and Medicaid Services, told reporters. The Congressional Budget Office has estimated that the negotiation program will save Medicare $100 billion over a decade. Many of the millions of Medicare enrollees who take the drugs subject to negotiation will see savings at the pharmacy counter, though it will depend on their Medicare Part D drug coverage, said Spencer Perlman, director of health care research at Veda Partners, a policy consulting firm for institutional investors. For many, medication costs are typically based on drugs’ list prices – before the rebates and discounts to the Part D plans – and those prices will be lower due to the program.”

Forbes: Biden Administration Strikes Deal To Cut Cost Of Expensive Medicare Drugs. 

• “In [a] statement released by the White House, President Joe Biden said [the] deal would result in $6 billion in savings for the taxpayer. The renegotiated prices will also lead to $1.5 billion in cumulative savings in out-of-pocket spending for medicare enrollees, the White House said. The deal covers 10 key drugs used to manage or treat diabetes, heart failure, blood clots, arthritis and blood cancers. In an accompanying statement, Vice President Kamala Harris called the announcement ‘lifechanging’ for many people and said additional prescription drugs will be selected each year ‘as part of our Medicare drug price negotiation program.’ Up to 15 additional Medicare drugs will be up for negotiation in 2025, followed by another 15 in 2026 and ‘up to 20 drugs every year after that,’ Harris said.”

The Associated Press: White House Says Deals Struck To Cut Prices Of Popular Medicare Drugs That Cost $50 Billion Yearly.

• “The Biden administration said Thursday that drug price negotiations will knock hundreds of dollars — in some cases thousands — off the list prices of 10 of Medicare’s most popular and costliest drugs. The discounts, agreed to after months of negotiations with drug manufacturers, range between 38% and 79% on the medication’s list price…”
• “Medicare spent $50 billion covering the drugs last year and taxpayers are expected to save $6 billion on the new prices, which do not go into effect until 2026. Older adults could save as much as $1.5 billion in total on their medications in out-of-pocket costs. Administration officials released few details about how they arrived at those calculations. The newly negotiated prices will impact the price of drugs used by millions of older Americans to help manage diabetes, blood cancers and prevent heart failure or blood clots. The drugs include the blood thinners Xarelto and Eliquis and diabetes drugs Jardiance and Januvia.”

Roll Call: CMS Announces Medicare Prices For First Negotiated Drugs.

• “The Biden administration announced Thursday that it has reached an agreement with drug manufacturers for all 10 high-cost drugs it entered into negotiations earlier this year, a major step in the implementation of the president’s drug pricing law. The long-awaited announcement marks the first time Medicare will set the prices it pays for Part D prescription drugs as laid out by a law passed by Congress in 2022.”
• “The Congressional Budget Office had predicted some $98.5 billion savings through fiscal 2031, with $3.7 billion in the savings in the first year alone.”

Healthcare Finance: Administration Reaches Negotiation Agreement On 10 Drugs.

• “In a bid to lower prescription drug prices, the Biden administration this week reached an agreement for new, lower prices for the 10 drugs selected for negotiations. These drugs, the White House said, are some of the most expensive and most frequently dispensed drugs in the Medicare program and are used to treat conditions such as heart disease, diabetes and cancer. The new prices will go into effect for people with Medicare Part D prescription drug coverage beginning January 1, 2026.”
• “As a hypothetical example, a senior with Medicare who takes Stelara pays a 25% coinsurance on the drug, which may amount to about $3,400 today for a 30-day supply. When the negotiated price goes into effect in 2026, CMS said that the same 25% coinsurance would cost the beneficiary about $1,100 before the person reaches the catastrophic cap, after which the beneficiary will pay no more out of pocket on their prescription drugs. A beneficiary’s actual costs will depend on their plan’s benefit design, the agency said.”
• “The selected drugs accounted for $56.2 billion in total Medicare spending, or about 20% of total Part D gross spending in 2023. Overall, CMS said total Part D gross spending for the 10 selected drugs more than doubled from 2018 to 2022, from about $20 billion to about $46 billion, an increase of 134%. Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs in 2022 for these drugs. The Office of the Assistant Secretary for Planning and Evaluation (ASPE) also released new data detailing historic pricing trends of the 10 drugs selected for the first cycle of the negotiation program. The report finds that from 2018 to 2023, list prices increased as much as 55%.”

Fierce Pharma: IRA Negotiations Slash Medicare Prices For Big Pharma Blockbusters By Up To 79%. 

• “The White House has revealed significantly reduced prices for 10 prescription drugs affected by the first wave of Medicare negotiations mandated by the Inflation Reduction Act (IRA), the Biden administration initiative that includes several measures designed to lower the cost of healthcare in the U.S. The reductions were sharp, with list prices for all but one of the 10 medicines sliced by at least 50%.”
• “Starting in 2027, the negotiation process will expand to another 15 drugs, with more to come in subsequent years. From the outset of the IRA’s passage into law, the pharma industry has attempted to fight back against the legislation tooth and nail, with Pfizer CEO Albert Bourla, Ph.D., at one point even referring to the Medicare pricing talks as ‘negotiation with a gun to your head.’ […] Since the bill was passed—and the companies affected by the first round of pricing negotiations were made known—major pharma outfits have repeatedly tried, and failed, to challenge the constitutionality of the IRA in court.”

***MEDIA ADVISORY FOR THURSDAY, AUGUST 15, 2024***

This week, Protect Our Care is hosting events across the country, including two events today with Senators Baldwin and Kaine, to celebrate the announcement of the final prices Medicare negotiated for the first ten drugs and mark the second anniversary of the Inflation Reduction Act. Thanks to the Biden-Harris administration and Democrats in Congress, Americans are saving more than ever on health costs: the cost of insulin is capped at $35 dollars, seniors are protected from drug company price hikes, seniors’ prescription drug costs will be capped at $2,000 dollars per year starting next year, and Medicare has the power to negotiate lower prescription drug prices.

At the same time, Donald Trump and MAGA Republicans are working to put health benefits on the chopping block, ripping away care and raising prices while giving tax breaks to drug and insurance companies. If they get their way, they’ll slash critical funding for Medicare and Medicaid, repeal the Inflation Reduction Act, erode access to reproductive health care, and put drug and insurance companies back in control, letting them charge outrageous prices for prescriptions. The contrast between the Biden-Harris administration and Trump’s Republican Party couldn’t be clearer.

VIRGINIA

WHO:
U.S. Senator Tim Kaine (D-VA)
Chlo’e Edwards, Policy Director at New Virginia Majority
Freddy Mejia, Policy Director at The Commonwealth Institute
Katie Baker, State Director of Protect Our Care Virginia
Medicare Storytellers

WHAT: Press Conference

WHEN: Thursday, August 15, 2024, at 2 PM ET

WHERE: Tuckahoe Area Library. 1901 Starling Dr, Henrico, Va. 23229

RSVP: Mia Fisher, [email protected]

WISCONSIN

WHO:
U.S. Senator Tammy Baldwin (D-WI)
Pat Dunn, health care advocate

WHAT: Virtual Press Conference

WHEN: Thursday, August 15, 2024, at 4 PM CT // 5 PM ET

RSVP: Zoom registration link (Registration required)

While Democrats Lower Drug Prices, Republicans Vow to Stop Medicare from Negotiating 

Washington, D.C. — Today, the Biden-Harris administration announced the new, lower prices for 10 of the highest-cost, most popular drugs taken by people on Medicare. These new prices are known as “maximum fair prices,” and are the highest prices drug companies are allowed to charge for these life-saving medications. Thanks to the historic action taken by Democrats in Congress and the Biden-Harris administration to pass the Inflation Reduction Act in 2022, Medicare was given the power to negotiate lower drug prices with manufacturers for the first time in the program’s history.

This announcement follows a long line of actions the Biden-Harris administration has taken to reduce prescription drug and health care costs for the American people. The Inflation Reduction Act also lowered drug prices for millions of seniors by capping insulin costs at $35 per month, limiting outrageous price hikes, and making recommended vaccines, like the shingles shot, free for people on Medicare. And starting in 2025, total out-of-pocket drug costs will be capped at $2,000 per year for seniors. In 2023, 10 million seniors received a free vaccine, and HHS estimates that 19 million seniors will save $400 or more per year thanks to the out-of-pocket cap.

At the same time, Donald Trump and Republicans in Congress are fighting to roll back this progress and repeal the Inflation Reduction Act’s historic measures to lower drug prices for seniors. Repealing these policies would cost seniors billions of dollars — only putting money back in the pockets of big drug companies.

In response, Protect Our Care Chair Leslie Dach issued the following statement:

“For too long, we’ve lived in a broken system that has allowed drug companies to charge whatever they want while hardworking Americans struggle to afford the medications they need to survive. This announcement is 40 years in the making. The Biden-Harris administration and Democrats in Congress stood up to the greed of big drug companies and won, and now prices will come down for millions of seniors. The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will give seniors long overdue relief while saving taxpayers billions of dollars: it’s a win-win for the American people. Meanwhile, after spending $100 million to try to stop the Inflation Reduction Act, drug companies are still working with their Republican allies to repeal the law and ban Medicare from negotiating lower prices. As the Biden-Harris administration delivers savings to seniors, the contrast with Republicans could not be more clear.”

Background

Today’s announcement includes the first set of drugs with prices negotiated by Medicare, and by February 2026, another 15 drugs will be selected for negotiation. The new negotiated prices take effect in January 2026. The first round of drugs includes:

• Eliquis which is sold by Bristol Myers Squibb to treat blood clots
• Enbrel which is sold by Amgen to treat arthritis and psoriasis
• Entresto which is sold by Novartis to treat heart failure
• Farxiga which is sold by AstraZeneca to treat diabetes
• Fiasp/NovoLog which is sold by Novo Nordisk to treat diabetes
• Imbruvica which is sold by AbbVie to treat leukemia and lymphoma
• Januvia which is sold by Merck to treat diabetes
• Jardiance which is sold by Boehringer Ingelheim to treat diabetes
• Stelara which is sold by Johnson & Johnson to treat psoriasis and Crohn’s disease
• Xarelto which is sold by Johnson & Johnson to treat blood clots

Washington, DC – Protect Our Care is releasing updated profiles of the first ten drugs whose prices will be lowered as a result of the Inflation Reduction Act. Following months of negotiations with drug manufacturers, the Biden-Harris administration is scheduled to announce the final prices this week. The Medicare Drug Price Negotiation Program will lower costs for some of the highest-cost prescription drugs on the market used to treat conditions like cancer, diabetes, and autoimmune disorders. 

The profiles show that millions of people rely on these drugs to stay alive, and while drug companies continue to rake in sky-high profits and reward shareholders and executives, these drugs are costing patients and taxpayers billions. While the Biden-Harris administration is working tirelessly to implement the Inflation Reduction Act, drugmakers and their Republican allies are working to strip Medicare’s power to negotiate lower drug prices and reverse all of the drug savings from the Inflation Reduction Act.

“Prescription drugs don’t work if people cannot afford to take them,” said Leslie Dach, chair of Protect Our Care. “For far too long, Americans have been forced to skip doses and choose between their health and putting food on the table. The Biden-Harris administration stood up to big drug companies and won a decades-long battle to lower the cost of prescription drugs for millions of Americans. While drug companies are lobbying to ban Medicare from negotiating, they are raking in billions in profits and rewarding their CEOs and shareholders instead of helping patients. It’s shameful that drug companies and their Republican allies want to roll back all of the progress made to help people afford the medications they need to survive.”

Read the profiles here:

• Eliquis
• Enbrel
• Entresto
• Farxiga
• Fiasp/Novolog
• Imbruvica
• Januvia
• Jardiance
• Stelara
• Xarelto 

***MEDIA ADVISORY FOR AUGUST 12 – AUGUST 19***

Protect Our Care Hosts 10+ Events With Elected Officials and Advocates 

This week, Protect Our Care will host events in 10 states to mark the second anniversary of the Inflation Reduction Act and celebrate the announcement of the final prices Medicare negotiated for the first ten drugs. Thanks to the Biden-Harris administration and Democrats in Congress, Americans are saving more than ever on health costs: the cost of insulin is capped at $35 dollars, seniors are protected from drug company price hikes, seniors’ prescription drug costs will be capped at $2,000 dollars per year starting next year, and Medicare has the power to negotiate lower prescription drug prices. 

At the same time, Donald Trump and MAGA Republicans are working to put health benefits on the chopping block, ripping away care and raising prices while giving tax breaks to drug and insurance companies. If they get their way, they’ll slash critical funding for Medicare and Medicaid, repeal the Inflation Reduction Act, erode access to reproductive health care, and put drug and insurance companies back in control, letting them charge outrageous prices for prescriptions. The contrast between the Biden-Harris administration and Trump’s Republican Party couldn’t be clearer.

Protect Our Care Inflation Reduction Act Anniversary Events

MONDAY, AUGUST 12

MINNESOTA

WHO:
Attorney General Keith Ellison
Dr. Kelly Morrison, OBGYN and former legislator
Nicole Smith-Holt, Insulin for All advocate
Nancy Florence, RN, home health care nurse

WHERE: View recording of call here.

TUESDAY, AUGUST 13

ARIZONA

WHO:
Dr. Jeffrey Reynoso, HHS Regional Director
Doug Hart, former President of Arizona Alliance for Retired Americans
Les Braswell, Honest Arizona

WHAT: Virtual Press Conference

WHEN: Tuesday, August 13, 2024, at 9 AM MT // 12 PM ET

WHERE: Register here (Registration required)

WEDNESDAY, AUGUST 14

OHIO

WHO:
State Representative Michele Grim (OH-43)
Woodmere Mayor Ben Holbert
John Kennedy, Insulin for All
Daniel van Hoogstraten, Protect Our Care Ohio

WHAT: Virtual Press Conference

WHEN: Wednesday, August 14, 2024 at 1 PM ET

WHERE: Register here (Registration required)

THURSDAY, AUGUST 15

WISCONSIN

WHO:
U.S Representative Gwen Moore (D-WI-04)
Health care advocates

WHAT: Virtual Press Conference

WHEN: Thursday, August 15, 2024, at 10:30 AM CT // 11:30 AM ET

WHERE: Register here (Registration required)

VIRGINIA

WHO:
U.S. Senator Tim Kaine (D-VA)
New Virginia Majority
Katie Baker, Protect Our Care Virginia
Health care advocates

WHAT: Press Conference

WHEN: Thursday, August 15, 2024, at 2PM ET

WHERE: Location TBA

NEVADA

WHO:
U.S. Representative Susie Lee (D-NV-03)
Donna West, Health Care Advocate
For Our Future
Protect Our Care Nevada

WHAT: Press Conference

WHEN: Thursday, August 15, 2024, at 2 PM PT // 5 PM ET

WHERE: Sun City Summerlin Community Center/Meeting Hall, 10360 Sun City Blvd, Las Vegas, NV 89134

FRIDAY, AUGUST 16

NORTH CAROLINA

WHO:
HHS Regional Director Antrell Tyson
State Rep. Maria Cervania
Vanessa Watson, Protect Our Care North Carolina

WHAT: Virtual Press Conference

WHEN: Friday, August 16, 2024 at 10:30 AM ET

WHERE: Registration Link to Come

NEW YORK

WHO:
Mondaire Jones, former U.S. Representative (D-NY-17)
Health care advocates

WHAT: Press Conference

WHEN: Friday, August 16, 2024 at 12 PM ET

WHERE: Location TBA

CALIFORNIA

WHO:
Florice Hoffman, Health care advocate
Izeah Chairez, Health care advocate

WHAT: Virtual Press Conference

WHEN: Friday, August 16, 2024 at 10 AM PT // 1 PM ET

WHERE: Register here (Registration required)

MONDAY, AUGUST 19

PENNSYLVANIA

WHO:
U.S. Representative Matt Cartwright (D-PA-08)
Michael Berman, Protect Our Care Pennsylvania
Health care advocates

WHAT: Press Conference

WHEN: Monday, August 19, 2024 at 10:30 AM ET

WHERE: Location TBA

President Biden, Vice President Harris, and Democrats in Congress have taken historic action to lower health care costs and save Americans thousands of dollars a year. By passing the Inflation Reduction Act, Democrats stood up to big drug companies and lowered the cost of prescription drugs and insulin. Democrats have also lowered premium costs for people who buy their own coverage and helped more Americans get affordable coverage through Medicaid. Bringing down the cost of health care gives families more breathing room and helps keep food on the table and a roof over heads for millions of people. Here’s the top five ways that the Biden-Harris administration and Democrats in Congress have lowered Americans’ health care costs: 

1. Seniors are saving more on drugs than ever before thanks to Medicare drug price negotiation and other cost saving measures. The Inflation Reduction Act created several measures to bring down the cost of prescription drug prices for seniors. The historic law gave Medicare the ability to negotiate drug prices for seniors. In 2023, Medicare announced the first 10 drugs that were selected for negotiation, which are taken by nearly 9 million seniors and account for 20 percent of Medicare’s annual Part D spending. The Inflation Reduction Act also capped out-of-pocket drug costs for seniors at $2,000 per year starting in 2025. When this provision goes into effect, it is estimated that nearly 19 million Americans will save an average of $400 each year. Additionally, 400,000 low-income seniors will receive more help affording prescription drugs through the Medicare Part D Low-Income Subsidy Program. President Biden, Vice President Harris, and Democrats in Congress also stopped big drug companies from price gouging. If pharmaceutical manufacturers are found raising prices faster than the rate of inflation, they are required to pay back Medicare the difference. In January 2024, 48 drugs were required to pay rebates due to this rule.However, if Trump is re-elected in November, these cost savings will be repealed. He wants to put drug companies back in charge, raising prices on prescription drugs, and taking away Medicare’s power to negotiate lower drug prices. During Trump’s first presidency, drug prices rose faster than the rate of inflation every year he was in office. Trump returning to office would be detrimental for American seniors who rely on lowered prices on medications to afford to pay rent and put food on the table.
2. Insulin is capped at $35 per month. President Biden and Democrats took on big drug companies and won. Under the Inflation Reduction Act, insulin copays for people on Medicare are capped at $35 per prescription each month, saving seniors hundreds of dollars on their health care costs. In 2020, there were more than 3.2 million insulin users on Medicare. Democrats efforts on lowering insulin costs for Medicare recipients has led to reduced prices on the market as well. Sanofi, Novo Nordisk, and Eli Lilly now cap their insulin prices for everyone at $35 a month, making up 90 percent of the insulin on the market.Trump has continuously attempted to take credit for lower insulin prices, but in reality insulin costs soared during his presidency, with insulin retailing for $300 a vial under Trump. A report found that as many as one in four of the 7.5 million Americans dependent on insulin were skipping or skimping on doses due to rising costs. Now, Trump and Republicans in Congress want to repeal the Inflation Reduction Act, which would eliminate the $35 insulin cap for seniors on Medicare and hike the cost of prescription drugs for seniors nationwide.
3. Health care premiums are lower for millions of families.Thanks to President Biden, Vice President Harris, and Democrats in Congress, the Inflation Reduction Act extended premium tax credits to make health care more affordable for millions of Americans. Over 14 million Americans are saving an average of $527 on monthly health insurance premiums and 80 percent of enrollees are able to find a health plan through the Marketplace for $10 or less per month. Premium tax credits are set to expire at the end of 2025. Democrats are trying to ensure Americans can continue saving by making these tax credits permanent.Republicans want to end tax credits that help make health affordable for lower- and middle-income Americans, but they support giving more tax breaks to the wealthy and big corporations, including drug and insurance companies. Ending these tax credits would mean a typical 60-year-old couple making $80,000 per year would see their premiums triple to over $24,000 and a family of four making $125,000 would see an average increase of $7,676.
4. Free vaccinations are now available for Medicare, Medicaid, and CHIP beneficiaries. Thanks to President Biden and Democrats in Congress, 50.5 million Medicare Part D beneficiaries can now get their shingles vaccinations free of charge. In 2020, nearly 4 million Medicare beneficiaries received the two-part shingles vaccination. With a single shot of Shingrix costing $212, seniors on Medicare Part D are saving over $400 on average compared to vaccinations in 2023. Additionally, over 94 million Medicaid recipients now benefit from better vaccination coverage thanks to The Inflation Reduction Act. Medicaid and CHIP state programs are now required to cover vaccines recommended by the CDC’s Advisory Committee on Immunization Practices without out-of-pocket costs. More accessible vaccinations will particularly help low-income families who rely on Medicaid, many of whom are people of color and people with disabilities.Republicans’ plan to overturn the Inflation Reduction Act would put the cost of shingles vaccinations back on seniors and would create a much larger problem for those on Medicaid.  With over 33 percent of Americans developing shingles at some point in their life, accessibility to vaccinations is paramount as people continue to age. While complications or death from shingles is not common, seniors with weakened immune systems are particularly vulnerable, with 30 percent of shingles hospitalizations occurring within this population. Republicans’ plan to gut Medicaid means millions of Americans would lose their health coverage, including seniors with long-term care needs, children in low-income families, people with disabilities and people suffering from mental illnesses.
5. American families are protected from surprise medical bills and have access to affordable coverage. Democrats and the Biden-Harris administration took additional actions to ensure more Americans can afford their health care. From implementing rules to protect Americans from surprise medical bills to fixing the “family glitch”, more Americans are saving money while getting the care they need. Since January 1, 2022, Americans have been protected from surprise medical bills from emergency room visits, non-emergency out-of-network visits at in-network facilities, and air ambulance services for out-of-network providers. These new rules are already preventing 1 million surprise medical bills per month. Previous to these rules going into effect, surprise bills cost people an average of $750 to $2,600.
   President Biden and Vice President Harris also fixed “family glitch,” allows more lower-income families to qualify for subsidized health coverage under the ACA, even if a family member qualifies for affordable, employee-only insurance. Prior to the Biden-Harris administration’s fix, the “family glitch” left 5 million low-income Americans ineligible for tax credits to reduce the cost of their insurance.Additionally, legislation signed by President Biden guarantees that kids can stay on Medicaid and CHIP for at least a full year before their parents must apply to renew their coverage. Health care coverage throughout childhood is an important indicator of success in school and in adulthood. Medicaid eligibility during childhood lowers the high school dropout rate, raises college enrollment, and increases four-year college attainment. For each additional year of Medicaid eligibility as a child, adults by age 28 had higher earnings and made $533 additional cumulative tax payments due to their higher incomes. President Biden and Vice President Harris are also doing everything in their power to stop GOP efforts to throw Americans off of Medicaid.Trump and Republicans have failed the American people time and time again. They are more worried about putting profits over people. During his 4 years in office, Trump tried to repeal the Affordable Care Act, throw families off of Medicaid, and raise costs on the American people.  If Trump is reelected, these trends will only continue. Trump is fully committed to slashing Medicaid’s budget by over 50 percent. Millions would lose coverage with one in four Americans counting on Medicaid for access to health care. The program serves people from all backgrounds, including children, mothers, people of color, working families, people with disabilities, rural Americans, and seniors – all of whom would be at risk if Trump comes to power.

***MEDIA ADVISORY FOR MONDAY, AUGUST 12 AT 1 PM CT // 2 PM ET***

As Second Anniversary of Inflation Reduction Act Nears, Speakers will Highlight Walz’s Leadership Amidst MAGA Republicans’ Threats to Take Away Health Care from Thousands of Minnesotans

MINNEAPOLIS – On Monday, August 12 at 1 PM CT // 2 PM ET, Attorney General Keith Ellison, Nicole Smith-Holt, Dr. Kelly Morrison and advocate Nancy Florence will join Protect Our Care Minnesota to highlight how Governor Tim Walz (D-MN) has championed better health care and lower costs for Minnesotans. Gov. Tim Walz is a health care champion with a demonstrated record of fighting to ensure that his constituents have access to affordable, high-quality health care. While in Congress he helped pass the Affordable Care Act, and he has since worked to safeguard and build on its success. Walz has fought to protect Medicaid and Medicare, lower prescription drug costs, and protect access to reproductive health care.

As the second anniversary of the Inflation Reduction Act nears, speakers will share that because of the Biden-Harris administration and Democrats, more Americans than ever before have health insurance, the cost of insulin is capped at $35 dollars, seniors are protected from drug company price hikes, and seniors’ prescription drug costs will be capped at $2,000 dollars annually starting next year. For the first time in history, Medicare is negotiating prescription drug prices with pharmaceutical companies to lower costs for seniors. These provisions add up to big savings for Minnesotans, giving families more breathing room to get by and keeping people healthy.

At the same time, Donald Trump and his vice presidential pick Senator JD Vance support extreme policies that threaten to raise costs, throw people off their coverage, and decimate the historic accomplishments of the Biden-Harris administration. If MAGA Republicans get their way, they’ll slash critical funding for Medicare and Medicaid, repeal the Inflation Reduction Act and the Affordable Care Act, erode access to reproductive health care, and put drug and insurance companies back in control, letting them charge outrageous prices for prescriptions Minnesotans need to stay healthy.

PRESS CALL:

WHO:
Attorney General Keith Ellison
Dr. Kelly Morrison, OBGYN and former legislator
Nicole Smith-Holt, Insulin for All advocate
Nancy Florence, RN, home health care nurse 

WHAT: Press Conference

WHEN: Monday, August 12, 2024 at 1 PM CT // 2 PM ET

WHERE: Zoom Webinar (Registration Required)